These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 34461180)

  • 1. Circulating microbiome DNA: An emerging paradigm for cancer liquid biopsy.
    Chen H; Ma Y; Liu Z; Li J; Li X; Yang F; Qiu M
    Cancer Lett; 2021 Aug; 521():82-87. PubMed ID: 34461180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel directions of precision oncology: circulating microbial DNA emerging in cancer-microbiome areas.
    You L; Zhou J; Xin Z; Hauck JS; Na F; Tang J; Zhou X; Lei Z; Ying B
    Precis Clin Med; 2022 Mar; 5(1):pbac005. PubMed ID: 35692444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microbiome dysbiosis and epigenetic modulations in lung cancer: From pathogenesis to therapy.
    Khan FH; Bhat BA; Sheikh BA; Tariq L; Padmanabhan R; Verma JP; Shukla AC; Dowlati A; Abbas A
    Semin Cancer Biol; 2022 Nov; 86(Pt 3):732-742. PubMed ID: 34273520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microbiome: A Supportive or a Leading Actor in Lung Cancer?
    Martins D; Mendes F; Schmitt F
    Pathobiology; 2021; 88(2):198-207. PubMed ID: 33352574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microbiome and Prostate Cancer: A Novel Target for Prevention and Treatment.
    Kustrimovic N; Bombelli R; Baci D; Mortara L
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dysbiosis of the Gut Microbiome is associated with Tumor Biomarkers in Lung Cancer.
    Liu F; Li J; Guan Y; Lou Y; Chen H; Xu M; Deng D; Chen J; Ni B; Zhao L; Li H; Sang H; Cai X
    Int J Biol Sci; 2019; 15(11):2381-2392. PubMed ID: 31595156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of the microbiome in cancer development and therapy.
    Bhatt AP; Redinbo MR; Bultman SJ
    CA Cancer J Clin; 2017 Jul; 67(4):326-344. PubMed ID: 28481406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microbiome Dysbiosis and Predominant Bacterial Species as Human Cancer Biomarkers.
    Shirazi MSR; Al-Alo KZK; Al-Yasiri MH; Lateef ZM; Ghasemian A
    J Gastrointest Cancer; 2020 Sep; 51(3):725-728. PubMed ID: 31605288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leveraging circulating microbiome signatures to predict tumor immune microenvironment and prognosis of patients with non-small cell lung cancer.
    Zhou X; You L; Xin Z; Su H; Zhou J; Ma Y
    J Transl Med; 2023 Nov; 21(1):800. PubMed ID: 37950236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The gut microbiome and melanoma: A review.
    Makaranka S; Scutt F; Frixou M; Wensley KE; Sharma R; Greenhowe J
    Exp Dermatol; 2022 Sep; 31(9):1292-1301. PubMed ID: 35793428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human oral microbiome dysbiosis as a novel non-invasive biomarker in detection of colorectal cancer.
    Zhang S; Kong C; Yang Y; Cai S; Li X; Cai G; Ma Y
    Theranostics; 2020; 10(25):11595-11606. PubMed ID: 33052235
    [No Abstract]   [Full Text] [Related]  

  • 12. Microbial Biomarkers for Lung Cancer: Current Understandings and Limitations.
    Huang J; Huang J
    J Clin Med; 2022 Dec; 11(24):. PubMed ID: 36555915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dysbiosis of skin microbiome and gut microbiome in melanoma progression.
    Mekadim C; Skalnikova HK; Cizkova J; Cizkova V; Palanova A; Horak V; Mrazek J
    BMC Microbiol; 2022 Feb; 22(1):63. PubMed ID: 35216552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of gut microbiome in modulating response to immune checkpoint inhibitor therapy in cancer.
    Naqash AR; Kihn-Alarcón AJ; Stavraka C; Kerrigan K; Maleki Vareki S; Pinato DJ; Puri S
    Ann Transl Med; 2021 Jun; 9(12):1034. PubMed ID: 34277834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Function and Molecular Mechanism of Commensal Microbiome in Promoting Malignant Progression of Lung Cancer.
    Wang H; Hu J; Wu J; Ji P; Shang A; Li D
    Cancers (Basel); 2022 Nov; 14(21):. PubMed ID: 36358812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Association of Oral Microbiome Dysbiosis with Gastrointestinal Cancers and Its Diagnostic Efficacy.
    Asili P; Mirahmad M; Rezaei P; Mahdavi M; Larijani B; Tavangar SM
    J Gastrointest Cancer; 2023 Dec; 54(4):1082-1101. PubMed ID: 36600023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gut Microbiome in Colorectal Cancer: Clinical Diagnosis and Treatment.
    Liu Y; Lau HC; Cheng WY; Yu J
    Genomics Proteomics Bioinformatics; 2023 Feb; 21(1):84-96. PubMed ID: 35914737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib.
    Amatu A; Schirripa M; Tosi F; Lonardi S; Bencardino K; Bonazzina E; Palmeri L; Patanè DA; Pizzutilo EG; Mussolin B; Bergamo F; Alberti G; Intini R; Procaccio L; Arese M; Marsoni S; Nichelatti M; Zagonel V; Siena S; Bardelli A; Loupakis F; Di Nicolantonio F; Sartore-Bianchi A; Barault L
    Front Oncol; 2019; 9():622. PubMed ID: 31355139
    [No Abstract]   [Full Text] [Related]  

  • 19. Cancer metabolites: promising biomarkers for cancer liquid biopsy.
    Wang W; Rong Z; Wang G; Hou Y; Yang F; Qiu M
    Biomark Res; 2023 Jun; 11(1):66. PubMed ID: 37391812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dynamic liquid biopsy components as predictive and prognostic biomarkers in colorectal cancer.
    Raza A; Khan AQ; Inchakalody VP; Mestiri S; Yoosuf ZSKM; Bedhiafi T; El-Ella DMA; Taib N; Hydrose S; Akbar S; Fernandes Q; Al-Zaidan L; Krishnankutty R; Merhi M; Uddin S; Dermime S
    J Exp Clin Cancer Res; 2022 Mar; 41(1):99. PubMed ID: 35292091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.